Dogwood Therapeutics (DWTX) Competitors $4.75 +0.25 (+5.56%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock DWTX vs. XLO, MRSN, LTRN, CLNN, LVTX, TELO, KZR, RNTX, KALA, and OKURShould you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Xilio Therapeutics (XLO), Mersana Therapeutics (MRSN), Lantern Pharma (LTRN), Clene (CLNN), LAVA Therapeutics (LVTX), Telomir Pharmaceuticals (TELO), Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), KALA BIO (KALA), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical products" industry. Dogwood Therapeutics vs. Its Competitors Xilio Therapeutics Mersana Therapeutics Lantern Pharma Clene LAVA Therapeutics Telomir Pharmaceuticals Kezar Life Sciences Rein Therapeutics KALA BIO OnKure Therapeutics Xilio Therapeutics (NASDAQ:XLO) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Which has preferable valuation & earnings, XLO or DWTX? Dogwood Therapeutics has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio Therapeutics$9.27M4.05-$58.24M-$0.84-0.86Dogwood TherapeuticsN/AN/A-$12.35M-$18.04-0.26 Is XLO or DWTX more profitable? Dogwood Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -585.54%. Dogwood Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xilio Therapeutics-585.54% -262.69% -64.01% Dogwood Therapeutics N/A N/A -34.74% Does the media refer more to XLO or DWTX? In the previous week, Dogwood Therapeutics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.89 beat Dogwood Therapeutics' score of 0.94 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Xilio Therapeutics Very Positive Dogwood Therapeutics Positive Which has more risk & volatility, XLO or DWTX? Xilio Therapeutics has a beta of -0.15, meaning that its share price is 115% less volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Do analysts recommend XLO or DWTX? Xilio Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 451.72%. Dogwood Therapeutics has a consensus target price of $10.00, indicating a potential upside of 110.53%. Given Xilio Therapeutics' higher possible upside, equities research analysts plainly believe Xilio Therapeutics is more favorable than Dogwood Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in XLO or DWTX? 54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 5.2% of Xilio Therapeutics shares are owned by insiders. Comparatively, 3.9% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryDogwood Therapeutics beats Xilio Therapeutics on 7 of the 13 factors compared between the two stocks. Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DWTX vs. The Competition Export to ExcelMetricDogwood TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.07M$2.92B$5.51B$9.39BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.2620.5428.2719.87Price / SalesN/A258.87424.8998.56Price / CashN/A42.3835.5357.53Price / Book-0.637.768.215.70Net Income-$12.35M-$55.11M$3.24B$257.71M7 Day Performance-4.81%1.94%0.43%0.89%1 Month Performance-0.63%12.55%7.84%11.09%1 Year PerformanceN/A0.64%28.19%16.58% Dogwood Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DWTXDogwood Therapeutics1.8777 of 5 stars$4.75+5.6%$10.00+110.5%N/A$9.07MN/A-0.265Gap UpXLOXilio Therapeutics2.8943 of 5 stars$0.70+0.2%$4.00+472.0%-26.2%$36.14M$6.34M-0.8370Positive NewsMRSNMersana Therapeutics4.1839 of 5 stars$0.30+5.1%$5.20+1,608.8%-84.9%$36.08M$40.50M-0.52150Positive NewsLTRNLantern Pharma2.9852 of 5 stars$3.15-3.1%$25.00+693.7%-11.3%$35.05MN/A-1.7120News CoverageHigh Trading VolumeCLNNClene3.4581 of 5 stars$3.87-0.8%$40.00+933.6%-23.1%$35.03M$340K-0.96100LVTXLAVA Therapeutics2.219 of 5 stars$1.32flat$3.17+139.9%-32.2%$34.72M$11.98M-1.2760TELOTelomir Pharmaceuticals3.5557 of 5 stars$1.15flat$15.00+1,204.3%-72.4%$34.23MN/A-2.741Positive NewsKZRKezar Life Sciences4.1523 of 5 stars$4.55-0.7%$39.50+768.1%-30.8%$33.46M$7M-0.4260News CoverageAnalyst ForecastRNTXRein TherapeuticsN/A$1.54+2.0%N/AN/A$33.45MN/A-0.549KALAKALA BIO3.9233 of 5 stars$5.28+3.5%$13.50+155.7%-23.8%$32.91M$3.89M-0.6430OKUROnKure Therapeutics3.5398 of 5 stars$2.39+0.4%$32.33+1,252.9%N/A$32.15MN/A-0.45N/ANews CoveragePositive NewsGap Down Related Companies and Tools Related Companies XLO Alternatives MRSN Alternatives LTRN Alternatives CLNN Alternatives LVTX Alternatives TELO Alternatives KZR Alternatives RNTX Alternatives KALA Alternatives OKUR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DWTX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DWTX Stock Alerts